These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 20102273)

  • 21. Drug-resistant human immunodefiency virus.
    Kozal MJ
    Clin Microbiol Infect; 2009 Jan; 15 Suppl 1():69-73. PubMed ID: 19220361
    [TBL] [Abstract][Full Text] [Related]  

  • 22. HIV-1 resistant strains acquired at the time of primary infection massively fuel the cellular reservoir and persist for lengthy periods of time.
    Ghosn J; Pellegrin I; Goujard C; Deveau C; Viard JP; Galimand J; Harzic M; Tamalet C; Meyer L; Rouzioux C; Chaix ML;
    AIDS; 2006 Jan; 20(2):159-70. PubMed ID: 16511408
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of human immunodeficiency virus type 1 subtype C on drug resistance mutations in patients from Botswana failing a nelfinavir-containing regimen.
    Doualla-Bell F; Avalos A; Gaolathe T; Mine M; Gaseitsiwe S; Ndwapi N; Novitsky VA; Brenner B; Oliveira M; Moisi D; Moffat H; Thior I; Essex M; Wainberg MA
    Antimicrob Agents Chemother; 2006 Jun; 50(6):2210-3. PubMed ID: 16723586
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Three-class-resistant human immunodeficiency virus type 1 variant in a drug-naive heterosexual couple.
    Razzolini F; Saladini F; Malincarne L; Vicenti I; Palladino N; Romano L; Francisci D; Zazzi M
    J Clin Microbiol; 2008 Nov; 46(11):3856-9. PubMed ID: 18845824
    [TBL] [Abstract][Full Text] [Related]  

  • 26. New viral fitness test helps determine regimens.
    AIDS Alert; 2002 Aug; 17(8):100-1. PubMed ID: 12647689
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ultradeep sequencing in the therapeutic management of HIV-1 infection at treatment initiation.
    Todesco E; Mercier-Darty M; Jung M; Bottero J; Boyd A; Marcelin AG; Calvez V; Morand-Joubert L
    J Antimicrob Chemother; 2015; 70(6):1919-20. PubMed ID: 25637517
    [No Abstract]   [Full Text] [Related]  

  • 28. Revisiting the concept of a genetic barrier to resistance.
    Rusconi S
    J HIV Ther; 2006 Dec; 11(4):81-3. PubMed ID: 17578211
    [No Abstract]   [Full Text] [Related]  

  • 29. Distinct patterns of natural selection in the reverse transcriptase gene of HIV-1 in the presence and absence of antiretroviral therapy.
    de S Leal E; Holmes EC; Zanotto PM
    Virology; 2004 Aug; 325(2):181-91. PubMed ID: 15246258
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Genetic characterization of complex inter-recombinant HIV-1 strains circulating in Spain and reliability of distinct rapid subtyping tools.
    Holguín A; Lospitao E; López M; de Arellano ER; Pena MJ; del Romero J; Martín C; Soriano V
    J Med Virol; 2008 Mar; 80(3):383-91. PubMed ID: 18205216
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Current insights into reverse transcriptase inhibitor-associated resistance.
    Wainberg MA; White AJ
    Antivir Ther; 2001; 6 Suppl 2():11-9. PubMed ID: 11678474
    [No Abstract]   [Full Text] [Related]  

  • 32. Infrequent transmission of HIV-1 drug-resistant variants.
    Yerly S; Jost S; Telenti A; Flepp M; Kaiser L; Chave JP; Vernazza P; Battegay M; Furrer H; Chanzy B; Burgisser P; Rickenbach M; Gebhardt M; Bernard MC; Perneger T; Hirschel B; Perrin L;
    Antivir Ther; 2004 Jun; 9(3):375-84. PubMed ID: 15259900
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Quasispecies variant dynamics during emergence of resistance to raltegravir in HIV-1-infected patients.
    Malet I; Delelis O; Soulie C; Wirden M; Tchertanov L; Mottaz P; Peytavin G; Katlama C; Mouscadet JF; Calvez V; Marcelin AG
    J Antimicrob Chemother; 2009 Apr; 63(4):795-804. PubMed ID: 19221102
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Understanding transmitted HIV resistance through the experience in the USA.
    Taiwo B
    Int J Infect Dis; 2009 Sep; 13(5):552-9. PubMed ID: 19136289
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Drug resistance mutations in HIV-1.
    D'Aquila RT; Schapiro JM; Brun-Vézinet F; Clotet B; Conway B; Demeter LM; Grant RM; Johnson VA; Kuritzkes DR; Loveday C; Shafer RW; Richman DD
    Top HIV Med; 2003; 11(3):92-6. PubMed ID: 12837968
    [No Abstract]   [Full Text] [Related]  

  • 36. Update of the drug resistance mutations in HIV-1: 2004.
    Johnson VA; Brun-Vézinet F; Clotet B; Conway B; D'Aquila RT; Demeter LM; Kuritzkes DR; Pillay D; Schapiro JM; Telenti A; Richman DD
    Top HIV Med; 2004; 12(4):119-24. PubMed ID: 15516709
    [No Abstract]   [Full Text] [Related]  

  • 37. Update of the drug resistance mutations in HIV-1: 2007.
    Johnson VA; Brun-Vézinet F; Clotet B; Günthard HF; Kuritzkes DR; Pillay D; Schapiro JM; Richman DD
    Top HIV Med; 2007; 15(4):119-25. PubMed ID: 17720996
    [No Abstract]   [Full Text] [Related]  

  • 38. Diversity of thymidine analogue resistance genotypes among newly diagnosed HIV-1-infected persons.
    García-Lerma JG
    J Antimicrob Chemother; 2005 Aug; 56(2):265-9. PubMed ID: 15951354
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A controlled trial of initial antiviral regimens for HIV-1 infection.
    Leiner S
    N Engl J Med; 2010 Mar; 362(9):854-5; author reply 855. PubMed ID: 20213882
    [No Abstract]   [Full Text] [Related]  

  • 40. The HIV-1 Non-subtype B Workgroup: an international collaboration for the collection and analysis of HIV-1 non-subtype B data.
    Kantor R; Shafer RW; Katzenstein D;
    MedGenMed; 2005 Feb; 7(1):71. PubMed ID: 16369376
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.